Skip to main content
PHVS
NASDAQ Life Sciences

Pharvaris Q3 2026: €283M Cash, Loss Widens to €47.4M Ahead of April 2027 PDUFA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$34.18
Mkt Cap
$2.4B
52W Low
$22.414
52W High
$43.25
52W Position info
52% above low
Off High info
21% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

PHVS sits 52% above its 52-week low of $22.414.

Summary

Pharvaris reported a €47.4M third-quarter loss and €283M in cash as of September 30, 2026, with commercial spending rising ahead of an April 23, 2027 FDA decision on deucrictibant IR.


Key Events · Earnings and Guidance · PHVS

  • Q3 Loss Widens on Commercial Build-Out

    Net loss for the quarter was €47.4M (€0.67 per share) versus €37.1M a year earlier, driven by G&A of €17.7M, up 79% year-over-year, and R&D of €32.4M, up 9%.

  • Cash of €283M After €128.8M Burn

    Cash and cash equivalents were €283M at September 30, 2026, down from €292M at December 31, 2025, after €128.8M of operating cash use in the nine months.

  • IR PDUFA Date Set for April 23, 2027

    The deucrictibant IR NDA for on-demand HAE treatment is under FDA review with a PDUFA action date of April 23, 2027; the EMA MAA is also under formal review.

  • XR Filing and CREAATE Data Timelines Held

    The XR NDA for HAE prophylaxis remains on track for 1H2027, and topline data from part 1 of the CREAATE AAE-C1INH study are expected in 1Q2027.


Analysis · PHVS · Life Sciences

The balance sheet still funds the launch build-out and the XR filing without an immediate raise: Pharvaris burned €128.8M of operating cash in the first nine months of 2026 and ended September with €283M. The cost side is the story. G&A jumped 79% year-over-year to €17.7M as the company hires a commercial team for a product that will not generate revenue until the FDA acts on deucrictibant IR, with a PDUFA date of April 23, 2027. Nothing in the pipeline slipped — CHAPTER-3 data remain the basis for an XR NDA in 1H2027 and CREAATE part 1 topline is now guided to 1Q2027 — but the widening loss raises the stakes on that approval, since a delay would force another financing.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PHVS was trading at $34.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $22.41 to $43.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PHVS - Latest Insights

PHVS
Oct 08, 2026, 6:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.68
Real-time Price: $34.18 info
Change: +$3.50 (+11%) info
Market Cap: $2.4B info
PHVS
Sep 17, 2026, 5:27 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $37.96
Real-time Price: $34.18 info
Change: -$3.78 (-10%) info
Market Cap: $2.4B info
PHVS
Sep 17, 2026, 5:27 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $37.96
Real-time Price: $34.18 info
Change: -$3.78 (-10%) info
Market Cap: $2.4B info
PHVS
Sep 08, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $42.40
Real-time Price: $34.18 info
Change: -$8.22 (-19%) info
Market Cap: $2.4B info
PHVS
Sep 08, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $38.90
Real-time Price: $34.18 info
Change: -$4.72 (-12%) info
Market Cap: $2.4B info